CTNM
Contineum Therapeutics, Inc. Class A Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$529.02M
P/E Ratio
—
EPS
$-1.94
Beta
0.89
52W High
$16.33
52W Low
$3.35
50-Day MA
$13.29
200-Day MA
$11.90
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-66.53M |
| Operating Margin | 0.00% |
| Return on Equity | -26.90% |
| Return on Assets | -18.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.69 |
| Price-to-Book | 2.17 |
| Price-to-Sales (TTM) | 11.15 |
| EV/Revenue | 8.25 |
| EV/EBITDA | 20.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $32.72M |
| Float | $25.40M |
| % Insiders | 0.98% |
| % Institutions | 93.84% |
Historical Volatility
HV 10-Day
63.36%
HV 20-Day
56.89%
HV 30-Day
50.24%
HV 60-Day
63.54%
HV Rank
1.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($22.00 target)
1
Strong Buy5
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026